NCT04850846View on ClinicalTrials.gov

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

January 29, 2025

Study Completion Date

July 31, 2027

Conditions
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Interventions
DRUG

Metformin XR

Orally by mouth

OTHER

Placebo

Orally by mouth

Trial Locations (7)

35053

Dana-Farber at NHOH, Londonderry

02115

Brigham and Women's Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

02135

Dana-Farber at Brighton, Brighton

01844

Dana-Farber at Merrimack Valley, Methuen

01757

Dana-Farber at Milford, Milford

02190

DF/ BWCC in Clinical Affiliation with South Shore Hospital, Weymouth

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER